JP2007523207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523207A5 JP2007523207A5 JP2007500151A JP2007500151A JP2007523207A5 JP 2007523207 A5 JP2007523207 A5 JP 2007523207A5 JP 2007500151 A JP2007500151 A JP 2007500151A JP 2007500151 A JP2007500151 A JP 2007500151A JP 2007523207 A5 JP2007523207 A5 JP 2007523207A5
- Authority
- JP
- Japan
- Prior art keywords
- depression
- disorder
- features
- disorders
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403998A GB0403998D0 (en) | 2004-02-23 | 2004-02-23 | Compounds |
| GB0425071A GB0425071D0 (en) | 2004-11-12 | 2004-11-12 | Compounds |
| PCT/EP2005/001939 WO2005080350A1 (en) | 2004-02-23 | 2005-02-21 | Pyrimidine derivatives as cannabinoid receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523207A JP2007523207A (ja) | 2007-08-16 |
| JP2007523207A5 true JP2007523207A5 (https=) | 2008-03-21 |
Family
ID=34889142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500151A Withdrawn JP2007523207A (ja) | 2004-02-23 | 2005-02-21 | カンナビノイド受容体モジュレーターとしてのピリミジン誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080261977A1 (https=) |
| EP (1) | EP1718620A1 (https=) |
| JP (1) | JP2007523207A (https=) |
| WO (1) | WO2005080350A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090275611A1 (en) * | 2006-04-07 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Compounds Which Modulate The CB2 Receptor |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| AU2010231694A1 (en) * | 2009-03-30 | 2011-10-06 | Astellas Pharma Inc. | Pyrimidine compound |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
| EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
| CN106146468B (zh) * | 2015-04-17 | 2020-12-01 | 杭州雷索药业有限公司 | 吡啶酮类蛋白激酶抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| AU726522B2 (en) * | 1995-09-01 | 2000-11-09 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US20060247261A1 (en) * | 2002-08-21 | 2006-11-02 | Eatherton Andrew J | Pyrimidine compounds |
| CA2619881A1 (en) * | 2005-08-16 | 2007-02-22 | Genzyme Corporation | Chemokine receptor binding compounds |
-
2005
- 2005-02-21 WO PCT/EP2005/001939 patent/WO2005080350A1/en not_active Ceased
- 2005-02-21 US US10/597,521 patent/US20080261977A1/en not_active Abandoned
- 2005-02-21 EP EP05715508A patent/EP1718620A1/en not_active Withdrawn
- 2005-02-21 JP JP2007500151A patent/JP2007523207A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520539A5 (https=) | ||
| JP2008501758A5 (https=) | ||
| JP2003511434A (ja) | モノアミン再取込み阻害剤として有用な新規ビアリールエーテル誘導体 | |
| JP2007523206A5 (https=) | ||
| JP2009534368A5 (https=) | ||
| CN106061964B (zh) | 能够刺激神经发生的n-苯基-内酰胺衍生物及其在神经性病症的治疗中的用途 | |
| JP2022515766A5 (https=) | ||
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| WO2007099423A1 (en) | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists | |
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2013540794A (ja) | 疼痛、精神病性障害、認知障害、またはアルツハイマー病の治療のためのアルファ‐７ニコチン性受容体修飾薬 | |
| RU2009136330A (ru) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| MXPA06014919A (es) | Derivados de cicloamino 1,3-sustituido y su uso como antagonitas del receptor de histamina-3. | |
| JP2005523335A5 (https=) | ||
| JP2007523207A5 (https=) | ||
| DK2614824T3 (en) | TRIAZOLD DERIVATIVES TO USE IN THE TREATMENT OF NEUROPATHIC PAIN AND FIBROMYALGIA | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| NO20092688L (no) | Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering | |
| KR20070086598A (ko) | 아릴- 및 헤테로아릴-치환 테트라히드로이소퀴놀린과노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 이의 용도 | |
| JP2007529495A5 (https=) | ||
| JP2010514682A5 (https=) | ||
| JP2007520537A5 (https=) | ||
| JP2006502157A5 (https=) |